Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05201703 · ClinicalTrials.gov registry record · Phase 4
Fycompa in Catamenial Epilepsy
A Phase 4 study, sponsored by University of Florida.
- Terminated
- Registry status
- Phase 4
- Development phase
- 7
- Enrollment target
NCT05201703 is a Phase 4 study that was terminated before completion, run by University of Florida. The registered enrollment target is 7 participants.
The verdict
NCT05201703, a Phase 4 study, was terminated before completion, sponsored by University of Florida.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 7 participants
- Enrollment target
Study Summary
The purpose of the proposed investigation is to carry out a pilot study of add-on perampanel (Fycompa) in women with perimenstural (C1) catamenial epilepsy. Perampanel, a noncompetitive AMPA receptor antagonist, is uniquely positioned to decrease progesterone receptor mediated excitotoxicity. This mechanism of action would allow a novel use of perampanel as an effective treatment of C1 catamenial epilepsy.
Interventions
- DRUG Fycompa
- DRUG Fycompa with a boost
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2022-03-09 |
| Est. Completion | 2023-12-15 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05201703
The ClinicalTrials.gov registry entry for NCT05201703 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Fycompa is the first listed.
NCT05201703 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05201703 about?
NCT05201703 is a clinical study titled "Fycompa in Catamenial Epilepsy". The purpose of the proposed investigation is to carry out a pilot study of add-on perampanel (Fycompa) in women with perimenstural (C1) catamenial epilepsy. Perampanel, a noncompetitive AMPA receptor antagonist, is uniquely positioned to decrease progesterone receptor mediated excitotoxicity. This m...
What is the current status of trial NCT05201703?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 7 participants. The study started on 2022-03-09. Estimated completion is 2023-12-15.
What interventions are being tested in trial NCT05201703?
The interventions under investigation include: Fycompa (DRUG), Fycompa with a boost (DRUG).
Who is sponsoring clinical trial NCT05201703?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.